<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02117999</url>
  </required_header>
  <id_info>
    <org_study_id>SEA_27</org_study_id>
    <secondary_id>PON01_00110</secondary_id>
    <nct_id>NCT02117999</nct_id>
  </id_info>
  <brief_title>Transepithelial Corneal Cross-linking Using Iontophoresis</brief_title>
  <acronym>T-ionto CL</acronym>
  <official_title>Randomized Clinical Trial Comparing Transepithelial Corneal Cross-linking Using Iontophoresis and Standard Corneal Cross-linking for the Treatment of Keratoconus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione G.B. Bietti, IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Consiglio Nazionale delle Ricerche, Istituto per i Processi Chimico-Fisici</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondazione G.B. Bietti, IRCCS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present Randomized Clinical Trial (RCT) is to compare the efficacy and
      safety of transepithelial corneal cross-linking using iontophoresis (T-ionto CL) to treat
      progressive keratoconus in comparison with standard cross-linking (standard CL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Keratoconus is a progressive corneal ecstatic disease causing visual impairment by inducing
      irregular astigmatism and corneal opacities. This disorder typically begins during the second
      decade of life and, in severe forms, may need a corneal transplantation. Corneal
      cross-linking is a procedure intended to halt keratoconus progression. It creates links
      between stromal proteins in order to stiffen the corneal tissue. Standard CL includes
      epithelial removal and stroma soaking with dextran-enriched 0.1% riboflavin solution for 30
      minutes before being exposed to ultraviolet-A radiation using a 3mW/cm2 lamp for 30 minutes.

      Epithelial debridement expose the cornea to a risk of side effects, such as pain for the
      first two post-operative days, temporary loss of visual acuity during the first three months,
      and serious complications such as infection and stromal opacity due to corneal scarring.

      Iontophoresis is a non invasive technique in which a weak electric current is used to enhance
      the penetration of hypotonic 0.1% riboflavin-5-phosphate solution into the corneal stroma
      through the intact epithelium. After iontophoresis, the corneal tissue is irradiated using a
      10 mW/cm2 for 9 minutes (T-ionto CL). From previous experimental work (Lombardo M. et al.
      JCRS 2014 and JCRS 2015), the investigators provided evidence that TCCionto increases the
      stiffness of human corneas with results almost comparable with standard CL. The new procedure
      thus holds the promise to be as effective as the standard procedure while minimizing all the
      related risks. It is object of the present clinical trial to randomize patients with
      progressive keratoconus to T-ionto CL and standard CL and compare efficacy and safety of
      treatments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Consecutive patients were randomized, using block randomization model, in one of the arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>K-max</measure>
    <time_frame>Changes from baseline in Kmax at 12 months</time_frame>
    <description>Measuring maximum keratometry (K-max) derived from computerized videokeratography.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corneal endothelial cell density</measure>
    <time_frame>Changes from baseline in ECD at 12 months</time_frame>
    <description>Endothelial cell density (ECD) will be evaluated using specular microscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Simulated keratometry</measure>
    <time_frame>Changes from baseline at 12 months.</time_frame>
    <description>Measures assessed by corneal tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical aberrations</measure>
    <time_frame>Changes from baseline at 12 months.</time_frame>
    <description>Optical aberrations of the eye will be measured using dynamic skyascopy. Corneal wavefront aberration will be measured using Placido disk topographer and Scheimpflug tomographer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>Changes from baseline at 12 months.</time_frame>
    <description>Visual acuity tested using ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast Sensitivity</measure>
    <time_frame>Changes from baseline at 12 months.</time_frame>
    <description>Contrast sensitivity tested using Pelli-Robson chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score</measure>
    <time_frame>Changes from baseline at 12 months.</time_frame>
    <description>PAin score will graded by the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central retinal thickness</measure>
    <time_frame>Changes from baseline at 12 months.</time_frame>
    <description>Central retinal thickness (1 mm ETDRS map) will be measured before and after CXL procedures</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Corneal biomechanical behaviour</measure>
    <time_frame>Changes from baseline at 12 months.</time_frame>
    <description>No-contact tonometry readings and strain response of the cornea to air-puff evaluated using ORA</description>
  </other_outcome>
  <other_outcome>
    <measure>Demarcation line</measure>
    <time_frame>Changes from baseline at 12 months.</time_frame>
    <description>OCT scans of the cornea will be acquired using Visante device</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Progressive Keratoconus</condition>
  <arm_group>
    <arm_group_label>Transepithelial corneal cross-linking using iontophoresis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transepithelial corneal cross-linking using iontophoresis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard corneal cross-linking</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard corneal cross-linking</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transepithelial corneal cross-linking using iontophoresis</intervention_name>
    <description>The procedure involves a constant current source and two electrodes. The active electrode is a bath tube, which includes a stainless steel grid, placed into the cup at a minimal distance from the cornea. The reservoir is filled with dextran-free, hypotonic riboflavin-5-phosphate solution. The generator applies a constant current of 1mA for a preset period of 5 min. After the riboflavin administration by iontophoresis, the cornea is irradiated using a UVA lamp of 10mW/cm2 for 9 minutes.</description>
    <arm_group_label>Transepithelial corneal cross-linking using iontophoresis</arm_group_label>
    <other_name>Ricrolin+</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard corneal cross-linking</intervention_name>
    <description>In the standard CL, the epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated using a UVA lamp of 3mW/cm2 for 30 minutes.</description>
    <arm_group_label>Standard corneal cross-linking</arm_group_label>
    <other_name>Ricrolin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of progressive keratoconus

        Exclusion Criteria:

          -  Anterior corneal curvature steeper than 61 D;

          -  central corneal thickness &lt;400 um

          -  corneal scarring;

          -  descemetocele;

          -  history of herpetic keratitis;

          -  Concomitant eye diseases;

          -  Inflammatory eye diseases;

          -  Glaucoma;

          -  Cataract;

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>46 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Lombardo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione G.B. Bietti, IRCCS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fondazione G.B. Bietti, IRCCS</name>
      <address>
        <city>Rome</city>
        <zip>00198</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.fondazionebietti.it</url>
    <description>Inclusion and exclusion criteria to the present RCT are shown in the main website page</description>
  </link>
  <reference>
    <citation>Spoerl E, Huhle M, Seiler T. Induction of cross-links in corneal tissue. Exp Eye Res. 1998 Jan;66(1):97-103.</citation>
    <PMID>9533835</PMID>
  </reference>
  <reference>
    <citation>Hao J, Li SK, Liu CY, Kao WW. Electrically assisted delivery of macromolecules into the corneal epithelium. Exp Eye Res. 2009 Dec;89(6):934-41. doi: 10.1016/j.exer.2009.08.001. Epub 2009 Aug 12.</citation>
    <PMID>19682448</PMID>
  </reference>
  <reference>
    <citation>Eljarrat-Binstock E, Domb AJ. Iontophoresis: a non-invasive ocular drug delivery. J Control Release. 2006 Feb 21;110(3):479-89. Epub 2005 Dec 15. Review.</citation>
    <PMID>16343678</PMID>
  </reference>
  <reference>
    <citation>Bikbova G, Bikbov M. Transepithelial corneal collagen cross-linking by iontophoresis of riboflavin. Acta Ophthalmol. 2014 Feb;92(1):e30-4. doi: 10.1111/aos.12235. Epub 2013 Jul 15.</citation>
    <PMID>23848196</PMID>
  </reference>
  <reference>
    <citation>Meek KM, Hayes S. Corneal cross-linking--a review. Ophthalmic Physiol Opt. 2013 Mar;33(2):78-93. doi: 10.1111/opo.12032. Review.</citation>
    <PMID>23406488</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2014</study_first_submitted>
  <study_first_submitted_qc>April 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2014</study_first_posted>
  <last_update_submitted>February 14, 2017</last_update_submitted>
  <last_update_submitted_qc>February 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondazione G.B. Bietti, IRCCS</investigator_affiliation>
    <investigator_full_name>Marco Lombardo</investigator_full_name>
    <investigator_title>Dr. Marco Lombardo</investigator_title>
  </responsible_party>
  <keyword>corneal cross-linking</keyword>
  <keyword>transepithelial corneal cross-linking</keyword>
  <keyword>iontophoresis</keyword>
  <keyword>progressive keratoconus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>March 29, 2017</submitted>
    <returned>June 15, 2017</returned>
    <submitted>June 16, 2017</submitted>
    <returned>January 26, 2018</returned>
    <submitted>January 27, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

